UPDATE 1-FDA extends review period for Forest Lab lung drug

Thu Mar 29, 2012 3:04am EDT

March 29 (Reuters) - Forest Laboratories and Almirall said a U.S. regulator has extended the review period for their inhaled drug that could be used to treat a certain type of lung disease.

The U.S. Food and Drug Administration will require a three-month extension to complete its review of the data supporting the new drug application for the drug, known generically as aclidinium bromide, the companies said.

The drug is used for the maintenance treatment of chronic obstructive pulmonary disease, a serious lung disease that makes breathing difficult and is often caused by cigarette smoking.

COPD is the fourth-leading cause of death in the United States and affects about 24 million people, according to the American Lung Association.

No additional data has been requested by the agency to complete the review. FDA action is now expected by July 2012, the companies said.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

A tourist takes a plunge as she swims at Ngapali Beach, a popular tourist site, in the Thandwe township of the Rakhine state, October 6, 2013. Picture taken October 6, 2013. REUTERS/Soe Zeya Tun (MYANMAR - Tags: SOCIETY) - RTR3FOI0

Where do you want to go?

We look at when to take trips, budget considerations and the popularity of multigenerational family travel.   Video